Back to Trial

Oracle Runs

Oracle findings and outcome history for Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML (NCT06191263).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 6:52 PM
Resolution Evidence
Outcome
YES
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

Sponsor public readouts for the exact Phase II RIVER-81/NCT06191263 trial clearly describe the study as showing promising activity, improved outcomes with optimized dosing, tolerability, and support for further exploration. Later company update also says the trial induced complete remissions with favorable safety.

Sources
Sponsorryvu.com6/12/25
Ryvu Therapeutics Presents Data on RVU120 at the European Hematology Association Congress 2025

For RIVER-81 Phase II, Ryvu said RVU120+venetoclax showed promising anti-leukemic activity; optimized dosing improved results, and the study supports further exploration with tolerated safety.

View source
Sponsorryvu.com11/20/25
Ryvu Therapeutics Reports Third Quarter 2025 Financial Results

Company update states Phase II RIVER-81 data suggest romaciclib restores venetoclax sensitivity in resistant AML, inducing complete remissions with a favorable safety profile.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

YESAccepted92% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Sponsor public readouts for the exact Phase II RIVER-81/NCT06191263 trial clearly describe the study as showing promising activity, improved outcomes with optimized dosing, tolerability, and support for further exploration. Later company update also says the trial induced complete remissions with favorable safety.

Found Apr 1, 2026, 6:52 PMOutcome date Jun 12, 2025, 12:00 AMReviewed Apr 1, 2026, 7:03 PM
Sponsorryvu.comJun 12, 2025, 12:00 AM
Ryvu Therapeutics Presents Data on RVU120 at the European Hematology Association Congress 2025
For RIVER-81 Phase II, Ryvu said RVU120+venetoclax showed promising anti-leukemic activity; optimized dosing improved results, and the study supports further exploration with tolerated safety.
Sponsorryvu.comNov 20, 2025, 12:00 AM
Ryvu Therapeutics Reports Third Quarter 2025 Financial Results
Company update states Phase II RIVER-81 data suggest romaciclib restores venetoclax sensitivity in resistant AML, inducing complete remissions with a favorable safety profile.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 7:03 PM

Will the results be positive?

PendingtoYEScurrentYES
GPT-5.4 (OpenAI)92% confidenceReviewed Apr 1, 2026, 7:03 PM

Sponsor public readouts for the exact Phase II RIVER-81/NCT06191263 trial clearly describe the study as showing promising activity, improved outcomes with optimized dosing, tolerability, and support for further exploration. Later company update also says the trial induced complete remissions with favorable safety.